Quoin Pharmaceuticals (QNRX) investor relations material

Executive summary

• Achieved FDA conditional approval for QYLEKI as the brand name for QRX003 targeting Netherton Syndrome, with QRX003 in pivotal registrational clinical testing in the US and internationally.

• Reported positive clinical update from pediatric compassionate use program in Netherton Syndrome, with 4 of 6 patients showing improvement and no treatment-related adverse events.

• Received U.S. Notice of Allowance for a patent covering combination treatment for Netherton Syndrome.

• Submitted and received FDA clearance for the first-ever IND for Peeling Skin Syndrome, enabling a Phase 2/3 study to begin in 2H 2026.

• Advanced QRX009 topical rapamycin platform toward clinical testing in multiple rare dermatologic indications.

Financial highlights

• Net loss for Q2 2026 was $5.4 million, compared to $3.7 million in Q2 2025; net loss for the six months ended June 30, 2026 was $10.4 million, up from $7.5 million year-over-year.

• Operating expenses for Q2 2026 were $5.47 million, up from $3.79 million in Q2 2025, with R&D at $3.54 million and G&A at $1.85 million.

• Cash, cash equivalents, and marketable securities totaled $10.8 million as of June 30, 2026.

• Accumulated deficit reached $81.3 million as of June 30, 2026.

• Company expects current cash position to fund operations into 2027.

Outlook and guidance

• Management has concluded there is substantial doubt about the ability to continue as a going concern for at least one year without additional funding.

• No revenue expected until successful development and marketing approval of product candidates, which is subject to significant uncertainty and expected to take years.

• Phase 2/3 study for Peeling Skin Syndrome expected to enroll pediatric and adult patients in the US and Europe, initiating in 2H 2026.

• IND submission for QRX009 in an additional indication planned before end of 2026.

• Plans to seek further funding through equity, debt, or strategic partnerships.